Funzol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Funzol

Quick Facts

Property Description
Active ingredient Fluconazole
Form Oral (tablet, capsule, suspension) and Intravenous (IV) solution
Pharmacological class Triazole Antifungal
General purpose Fights systemic and local fungal infections
Origin Synthetic

What Type of Medicine is Funzol?

Funzol is a synthetic antifungal medicine that contains the active ingredient Fluconazole, belonging to the triazole class of antifungal agents. This drug is manufactured chemically and is used to target infections caused by various yeast and fungal organisms.

Fluconazole is a flagship agent in its class and is a cornerstone in the treatment of many fungal conditions due to its established efficacy and predictable absorption profile. Its systemic nature—meaning it travels through the bloodstream—differentiates it from topical creams and is essential for treating internal or widespread fungal diseases.


How is Funzol Supplied and Composed?

Funzol is supplied in multiple forms for both oral (by mouth) and intravenous (IV) administration, allowing for high flexibility in treatment settings. The core component in all formulations is Fluconazole, whether it is compounded into tablets, capsules, or a sterile solution for injection.

The drug achieves excellent absorption when taken orally, with a high oral bioavailability of above 90%. This feature enables healthcare providers to transition patients from immediate hospital IV treatment to convenient oral therapy at home.

What side effects are possible with Funzol?

Possible Side Effects and Safety Information

The safety profile of Funzol (Fluconazole) is documented across several classifications in official regulatory labeling, including categorization by frequency and affected organ system.

Adverse reactions are primarily classified by their incidence rate. The Very Common (1/10) adverse reaction documented is headache. The Common (1/100 to < 1/10) reactions include nausea, abdominal pain, diarrhea, vomiting, rash, and elevations in liver enzymes (ALT, AST, Alkaline Phosphatase), indicating effects on the Gastrointestinal and Hepatobiliary Systems. Less common reactions may affect the nervous system, leading to dizziness or seizures.


Serious Adverse Reactions and Key Constraints

Official documents highlight the potential for severe reactions, including Serious Hepatic Toxicity (e.g., hepatic failure), which may occur regardless of the dose or duration of therapy. Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, and serious allergic responses like anaphylaxis, are documented as rare but significant risks. The regulatory label also notes the potential for QT interval prolongation and Torsades de pointes, which are serious cardiac rhythm disturbances.

Safety constraints include absolute contraindications for individuals with known hypersensitivity to Fluconazole or other azole agents, and restrictions on concomitant use with certain medications (e.g., Cisapride) due to a high risk of serious cardiac interaction. The label also contains population-specific safety notes, particularly the need for dose adjustment in patients with Renal Impairment and the association of high-dose, long-term use during pregnancy with certain risks.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Funzol (Fluconazole) describes specific clinical manifestations and mandated emergency actions in the event of an overdose.

Documented presentations primarily involve the Central Nervous System, which includes hallucination, paranoid behaviour, fearfulness, suspiciousness, or other notable mental changes.

An overdose also carries the regulatory warning of potential severe cardiovascular effects. These documented risks include QT prolongation and the serious, life-threatening heart rhythm disorder known as Torsade de pointes.

Regulators mandate that in the event of any suspected overdose, individuals must seek immediate medical attention. Urgent medical help is specifically required if the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened, necessitating an immediate call to emergency services.

Official Management Statements
Antidote: No specific antidote is known.
Treatment: Management consists of symptomatic treatment and supportive measures.
Elimination: Procedures may include gastric lavage (if necessary) or haemodialysis, which is documented to reduce the drug’s plasma concentration by approximately 50%.

Therapeutic Uses of Funzol

Funzol (Fluconazole) is commonly used to help with a spectrum of fungal and yeast afflictions, playing a role in managing symptoms across both widespread and localized infections. This medication is utilized for conditions presenting with acute episodes of severe fungal conditions.

Therapeutic Scope and Benefit

The medication is relevant for easing symptom clusters that may become intense or disruptive in mucosal areas, including the mouth, throat, and vagina, as well as being applied to systemic conditions like fungal bloodstream infections (Candidemia) and Cryptococcal Meningitis. It assists with maintaining functional stability in serious diseases and contributes to improved comfort during episodes of localized irritation.

“It plays a role in managing prevention (prophylaxis) against fungal disease in highly vulnerable patients.”

Funzol is relevant for managing symptoms in situations involving recurrent or episodic manifestations and is commonly used to assist with managing recurrence in serious infections, thereby supporting the patient in maintaining a sense of stability when fungal risks are more noticeable.

Quick Fact: Relief for Fungal Symptoms
Systemic Use: Applied when symptoms are related to systemic imbalance and organ-specific functional stress.
Local Use: Relevant for easing symptoms related to inflammatory or irritative states in mucosal areas.

This treatment provides support that helps ease the overall symptom burden, whether addressing acute oral thrush, vaginal candidiasis, or supporting stability in patients with severe, deep-seated disease.

Regulatory References

  1. Fluconazole: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Funzol

This section describes the official restrictions and contraindications for Funzol (fluconazole) as outlined in governmental regulatory documents.

Populations for Whom Use is Prohibited

Use of Funzol is contraindicated (prohibited) for patients with a known hypersensitivity or allergic reaction to fluconazole, related azole substances, or any excipients in the formulation.

Co-administration with several medicines is also strictly contraindicated, including but not limited to cisapride, astemizole, pimozide, quinidine, and erythromycin. This is due to the risk of serious and potentially fatal heart rhythm abnormalities, particularly QT prolongation, when used with these specific drugs metabolized via the CYP3A4 enzyme.

Required Caution and Restrictions

  • Pregnancy and Lactation: Use is generally not recommended during pregnancy, especially for chronic high-dose therapy, due to potential harm to the fetus. Women of child-bearing potential should use effective contraception during treatment and for approximately one week after the final dose. Use during breastfeeding should be determined cautiously by a healthcare provider.
  • Organ Impairment: Patients with kidney dysfunction require a careful dosage adjustment for multiple doses based on their level of renal clearance. Patients with liver dysfunction require close monitoring, and treatment must be discontinued if clinical signs of liver disease develop.
  • Cardiac Conditions: Use requires caution in patients with pre-existing heart conditions (including structural heart disease or advanced cardiac failure) and electrolyte abnormalities (e.g., low potassium), due to an increased risk of serious heart rhythm changes.
  • Age: While generally established for children and adults, dosing is adjusted for neonates and infants, and older adults may require dose adjustments if they have reduced kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Funzol (Fluconazole) has a documented interaction profile primarily structured around its activity as an inhibitor of specific hepatic enzymes. Officially, Funzol is classified as a strong inhibitor of CYP2C19 and a moderate inhibitor of both CYP2C9 and CYP3A4. This mechanism leads to reduced clearance and increased plasma concentrations of many co-administered medicines metabolized by these pathways.

Contraindicated Combinations

Co-administration with several substances is contraindicated due to the risk of severe cardiotoxicity (e.g., QT prolongation) resulting from increased exposure. These prohibited combinations include Astemizole, Cisapride, Pimozide, Quinidine, and Erythromycin. Use with Terfenadine is also contraindicated when the Funzol dose is 400 mg per day or higher.

Exposure Modification and Restrictions

Substance Official Interaction Outcome
Abrocitinib Systemic exposure (AUC) is increased approximately 4.8-fold. Co-administration must be avoided.
Rifampicin Decreases Funzol (Fluconazole) AUC by 25%.
Hydrochlorothiazide Increases Funzol plasma concentrations by 40%.
Warfarin, Cyclosporine, Tacrolimus Plasma concentrations are significantly increased; monitoring is required.

Funzol may be taken without regard to meals, as food does not significantly affect its absorption.

Mechanism of Action

Targeted Inhibition of Fungal Enzyme Synthesis

Funzol (Fluconazole) initiates its action by targeting the essential fungal enzyme Cytochrome P450 14alpha-demethylase (14alpha-DM). The drug acts as a selective inhibitor, binding to the enzyme's active site and immediately halting its catalytic function. This molecular blockade begins the core mechanistic cascade leading to the cellular consequence.


Sabotage of the Fungal Cell Membrane

The inhibition of the 14alpha-DM enzyme prevents the fungus from completing the ergosterol biosynthesis pathway. This causes a severe deficiency of ergosterol, the necessary lipid for maintaining cell membrane structure, and concurrently leads to the accumulation of toxic intermediate sterols. The physiological consequence is a compromised, leaky, and structurally rigid fungal membrane. This membrane dysfunction supports the cessation of fungal cell growth and replication.


Mechanisms Limiting Functional Expression

The mechanism's functional expression is constrained by fungal biological responses, primarily involving acquired resistance. This involves the target fungus developing specific genetic mutations in the ERG11 gene that reduce Funzol's binding affinity, or by overexpressing cellular efflux pumps (such as CDR1) that facilitate the rapid expulsion of the drug, resulting in non-inhibitory intracellular concentrations.

Dosage and Administration Information

Funzol (Fluconazole) is administered via two standard methods: the oral route (capsules, tablets, or liquid suspension) and intravenous (IV) infusion. The high oral absorption profile allows for the transition from IV treatment in a specialized setting to convenient oral therapy once the patient is clinically stable. The daily dosage is consistent regardless of the route of administration.

Usage follows established pharmacological timing. For multi-day regimens, administration is typically once daily. Treatment often begins with an initial loading dose—frequently double the maintenance dose—on the first day to rapidly achieve effective drug concentrations. The overall duration is highly variable, ranging from a single oral dose for acute localized conditions to several weeks or months of continuous use for deep-seated systemic infections.

Special procedural considerations apply to ensure appropriate drug exposure. The intravenous solution is administered at a controlled infusion rate not exceeding 10 mL per minute. For the oral liquid suspension, the product is shaken well before use. Dosing adjustments are utilized for specific populations; for adult patients with renal impairment, the maintenance dose is typically reduced by 50%, while pediatric dosing is determined based on body weight (mg/kg).

Recent Clinical Evidence

Research evidence / Overview of studies for Funzol (Fluconazole)

This overview summarizes the official research evidence from clinical trials and authoritative sources describing the use of Funzol (Fluconazole) for various conditions. It describes the types of studies that have been conducted and the outcomes that researchers monitored, without offering any clinical advice or interpretation of personal outcomes.


Evidence for Systemic Fungal Bloodstream Infections

The research base for severe, widespread fungal infections in the bloodstream, such as candidemia, relies on a significant number of Randomized Controlled Trials (RCTs) and systematic reviews exploring the use of the medicine alongside other treatments. These studies were evaluated in hospitalized and critically ill patients to explore approaches for managing serious systemic or functional imbalance.

Researchers monitored outcomes related to overall survival and mycological eradication measurements (fungal clearance from blood cultures). Trials also described patterns observed when the medicine was studied for use alongside other classes of antifungal treatments.

Studies on Fungal Meningitis

The evidence for treating fungal meningitis (such as Cryptococcal Meningitis) is primarily based on RCTs and prospective studies. This research was studied for use in patients facing conditions associated with acute or disruptive episodes, particularly adults with HIV infection and severe immunosuppression.

Key outcomes researchers monitored related to central nervous system functional stability, specifically the rate of Cerebrospinal Fluid (CSF) sterilization (clearance of the fungus from the spinal fluid) and long-term survival outcomes. Studies describe how the medicine was studied for use over an extended period as maintenance therapy to examine outcomes related to the recurrence of the infection in highly immunosuppressed patients.


What Remains Uncertain About the Research

Evidence quality varies across studies, especially in older or smaller trials, which means that subgroup findings are uncertain in some specialized areas. Comparative evidence is lacking for certain indications, making it difficult to fully contextualize some findings. Research is ongoing to fully understand management approaches for fungal strains that have shown resistance in laboratory settings.

It is important to understand that research findings describe group patterns, not personal outcomes. The evidence provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Guidelines for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America (IDSA)
  2. Fluconazole: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Funzol (FAQ)


Q: How quickly can I expect Funzol to start working?

Studies and official information indicate that Funzol is rapidly absorbed after an oral dose. Pharmacokinetic data shows that the highest concentrations of the drug in the blood are typically reached within one to two hours. This rapid absorption is the mechanism by which the drug achieves effective concentrations.


Q: What happens if I stop taking Funzol suddenly?

Regulatory documents state that the duration of treatment with Funzol should be determined by the clinical response to the infection being treated. The official product information notes that stopping the medicine too early may be associated with the return of the infection.


Q: Is it normal to feel tired when starting Funzol?

Official information documents common adverse reactions such as headache, and less common effects on the Nervous System, which include dizziness. While tiredness itself may not be explicitly listed as a common effect, these are generally related to how a medicine can affect the central nervous system.


Q: Can Funzol affect my sleep patterns?

Adverse reaction listings describe less common events involving the nervous system, such as dizziness and seizures. However, the official product information does not generally list specific effects on sleep patterns, such as insomnia, as common reactions.


Q: Are there any long-term side effects associated with Funzol?

Official labeling highlights the potential for certain serious adverse reactions, such as severe hepatic (liver) toxicity and severe cutaneous (skin) adverse reactions, which may occur regardless of the dose or duration of treatment.


Q: Can Funzol be taken with common pain relievers like ibuprofen?

Official information classifies Funzol as a moderate inhibitor of certain liver enzymes, specifically CYP2C9. This can result in increased concentrations of other medicines that are processed by this pathway, which includes some common non-prescription pain relievers. This mechanism indicates that co-administration may require monitoring, as described in regulatory documents.


Q: Does Funzol interact with caffeine?

Regulatory documents detail that Funzol inhibits certain liver enzymes. While caffeine is processed by a pathway that may be affected by the drug, it is not typically listed as a clinically significant interaction in the primary official product information.


Q: Can Funzol interact with herbal remedies, such as St. John's wort?

Official documents caution against co-administration with other medicines that affect liver enzymes. Some herbal products are known to alter the concentration of medicines in the body, and the official label notes that this can result in reduced concentrations of Funzol.


Q: Is Funzol safe for older adults (seniors)?

The official label addresses the use of Funzol in older adults. The regulatory information describes that dose adjustments are necessary if an older adult patient has reduced kidney function, because drug clearance may be slower in this population.


Q: What is the recommended time of day to take Funzol?

Official product information states that the medicine is generally taken once daily. The specific time of day is typically not specified because its absorption is not affected by whether it is taken with or without food.


Q: Can Funzol be cut in half or crushed?

The official product information describes the intended use and physical form of the oral medicine. There are generally no instructions in the prescribing information for physically altering the tablets or capsules, and the oral suspension is intended to be used as dispensed.


Q: Does Funzol cause 'brain fog' or concentration issues?

Regulatory documents list less common adverse reactions that involve the nervous system, such as dizziness and seizures. These are neurological events that may be associated with changes in mental clarity or concentration.


Q: What is the maximum duration of use that has been studied for Funzol?

Clinical trial sections describe a wide range of treatment durations. Use can range from a single oral dose for acute, localized conditions to extended regimens lasting several months for severe systemic infections.


Q: Is Funzol known to be habit-forming?

Funzol (Fluconazole) is classified as an antifungal medicine belonging to the triazole class. It is not designated as a controlled substance by major regulatory bodies.


Q: Does Funzol have benefits other than its main use?

In addition to treating active fungal infections, Funzol is officially indicated for the prophylaxis, or prevention, of certain fungal infections in specific high-risk patient populations, according to regulatory documents.


Q: Can children or teenagers use Funzol?

Official documents confirm that dosing for pediatric patients is established and based on the child's body weight (mg/kg). This approach allows for appropriate use across different age ranges, including children and teenagers.


Q: Is Funzol appropriate for people with kidney problems?

The regulatory label indicates that a reduction in the maintenance dose is necessary for patients with renal impairment, due to how the body clears the drug.


Q: Can Funzol affect my ability to get pregnant?

For women of child-bearing potential, regulatory documents contain a statement that effective contraception should be used during treatment and for approximately one week after the final dose. This addresses the potential for the medicine to affect a pregnancy.


Q: Is it necessary to have routine blood tests while on Funzol?

Due to the potential for serious liver toxicity noted in the official labeling, the documents state that liver function monitoring is necessary, and interruption of treatment may be considered if clinical signs of liver disease develop.


Q: How long does Funzol stay in your system after the last dose?

Pharmacokinetic data from regulatory sources describe the drug's elimination based on its plasma half-life. The average half-life is approximately 30 hours, which determines how long the medicine remains in the body.


Q: Are there different strengths of Funzol available?

The official regulatory label lists the commercially available dosage forms and strengths for the oral medicine, which typically include 50 mg, 100 mg, 150 mg, and 200 mg capsules.


Q: Does Funzol contain any common allergens, like lactose or gluten?

Official documents list all excipients, or inactive ingredients, in the product formulation. This list contains the information necessary to check for the presence of specific substances like lactose or gluten.


Q: What kind of monitoring is described for patients starting Funzol?

Official warnings describe that monitoring of liver function is necessary. The documents also describe the need for caution in patients with pre-existing heart conditions or electrolyte abnormalities due to the risk of serious cardiac rhythm changes.


Q: Are there known drug-drug interactions with common cold medications?

The label identifies the specific liver enzymes inhibited by Funzol (CYP2C19, CYP2C9, and CYP3A4). This information provides the context needed to assess the potential for interaction with other medicines.


Q: Does Funzol cause any serious but rare side effects?

The regulatory label documents serious adverse reactions, which are rare, including Severe Cutaneous Adverse Reactions (SCARs) and potentially serious cardiac rhythm issues, such as Torsades de pointes.


How should Funzol be stored and disposed of?

Funzol (fluconazole) requires specific storage conditions to maintain its effectiveness. Oral tablets and the dry powder for oral suspension should be stored at controlled room temperature, typically below 25 C or 30 C, depending on the specific formulation, and protected from excessive moisture.

Formulation Storage Conditions
Tablets/Dry Powder Store below 25 C or 30 C. Keep tightly closed.
Reconstituted Suspension Store between 5 C and 30 C. Discard any unused portion after 14 days.

All forms must be kept out of the reach of children. Do not use Funzol if the expiration date has passed or the packaging appears damaged. To dispose of unused or expired medicine, follow local guidelines for drug take-back programs or consult a pharmacist for advice on safe disposal methods. Do not flush Funzol down the toilet or pour it down a drain unless specifically instructed to do so by a healthcare authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Funzol found in:

A-Z Index: